Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has received U.S. Food and Drug Administration approval for its Investigational New Drug application for Lucid-MS (Lucid-21-302), allowing the company to proceed with Phase 2 clinical development of its first-in-class multiple sclerosis (MS) candidate. The upcoming randomized, double-blind, placebo-controlled study will assess the drug's efficacy, safety, and tolerability in MS patients using both clinical and radiological measurements. Site selection is already underway, with patient enrollment and dosing expected to begin as soon as possible.
The significance of this milestone lies in Lucid-MS's novel mechanism of action. Unlike current MS therapies that primarily modulate the immune system, Lucid-MS aims to provide neuroprotection by inhibiting demyelination—the process that damages the protective myelin sheath around nerve fibers. Specifically, the drug targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. Preclinical models have demonstrated that Lucid-MS can prevent and even reverse myelin breakdown, a potential breakthrough for a disease where existing treatments often fall short in halting disability progression.
Prior Phase 1 trials in healthy participants reported that Lucid-MS was well tolerated with a favorable safety profile. The company also noted that it held more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, which may help fund the upcoming trials. For more details, the full press release is available at https://ibn.fm/HyWYH.
The FDA's clearance is a pivotal step for Quantum BioPharma, which is dedicated to building a portfolio of innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on developing Lucid-MS as a leading candidate. This progress underscores the potential of targeting PAD2 as a disease-modifying approach in MS, offering hope for a therapy that directly addresses the underlying neurodegeneration.
As Quantum BioPharma advances Lucid-MS into Phase 2, the medical community will be watching closely for evidence that this neuroprotective strategy can translate into meaningful clinical benefits for people living with MS. The initiation of this trial marks a critical step in potentially reshaping the treatment landscape for this chronic, debilitating condition.
